Estrone (E1): What Your Number Changes About Your Treatment

What Estrone (E1) Actually Measures

Estrone is one of three naturally occurring estrogens, alongside estradiol (E2) and estriol (E3). Before menopause, the ovaries secrete estradiol as the principal estrogen, and estrone plays a secondary role. After the final menstrual period, ovarian estradiol output drops by roughly 90%, and estrone becomes the predominant circulating estrogen because adipose tissue continuously converts androstenedione via the aromatase enzyme [1].

A serum estrone test measures the total concentration of estrone in nanomoles per liter or picograms per milliliter. Most U.S. Labs report in pg/mL. The test is ordered to assess postmenopausal estrogen status, investigate abnormal uterine bleeding, evaluate estrogen-producing tumors, or monitor hormone therapy.

Why Estrone Matters More After Menopause

Postmenopausal women with higher adipose mass produce more estrone because adipose aromatase activity scales with fat cell volume [2]. This is clinically relevant: estrone binds estrogen receptors with lower affinity than estradiol, yet chronic elevation still drives endometrial proliferation and may contribute to breast tissue stimulation [3].

The Endocrine Society's 2022 menopause guidelines state that "measurement of serum estradiol and, where indicated, estrone provides the most direct assessment of circulating estrogen bioavailability in postmenopausal women" [4]. Estrone alone does not tell the full story, but in the absence of exogenous estradiol it is the dominant signal.

Assay Method Affects Accuracy

Immunoassay-based estrone measurements become unreliable at concentrations below about 20 pg/mL, precisely the range most relevant to postmenopausal women. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) provides accurate quantification down to 1 to 2 pg/mL [5]. If your lab report does not specify the method, ask. An immunoassay result of "10 pg/mL" in a postmenopausal woman carries wide uncertainty; the same number by LC-MS/MS is clinically actionable.

Normal Estrone (E1) Ranges by Life Stage

Reference ranges shift substantially across reproductive life. The table below summarizes values from published endocrine reference data [6].

| Life Stage | Typical Estrone Range (pg/mL) | |---|---| | Premenopausal, follicular phase | 17 to 200 | | Premenopausal, luteal phase | 32 to 200 | | Postmenopausal (no HRT) | 7 to 40 | | Postmenopausal (oral estradiol) | 30 to 100+ | | Postmenopausal (transdermal estradiol) | 15 to 60 | | Prepubertal | <16 | | Male (adult) | 10 to 60 |

These ranges are not treatment targets. They describe what is observed in the stated populations. Whether any individual's number is "normal for them" depends on symptom burden, bone density, cardiovascular risk, and the presence or absence of a uterus.

The E1:E2 Ratio as a Clinical Signal

In untreated postmenopausal women, estrone typically exceeds estradiol, giving an E1:E2 ratio greater than 1.0. Oral estradiol supplementation raises both hormones but disproportionately elevates estrone because first-pass hepatic metabolism converts much of the ingested estradiol to estrone [7]. Transdermal delivery bypasses the liver and keeps the E1:E2 ratio lower, which is one reason many clinicians prefer the transdermal route.

A ratio inversion, where E2 climbs far above E1, can signal over-supplementation with injectable or pellet estradiol or the presence of an estrogen-secreting ovarian tumor.

Estrone in Men and Transgender Women

Men produce estrone primarily through peripheral aromatization of testosterone and androstenedione. Normal adult male levels run 10 to 60 pg/mL. Transgender women receiving gender-affirming estradiol therapy show rising E1 alongside E2, with the specific ratio depending on route [8]. Monitoring estrone alongside estradiol in this population helps detect over-conversion and guides dose adjustments.

What a Low Estrone Result Means for Your Treatment

A postmenopausal estrone below 15 pg/mL, confirmed by LC-MS/MS, suggests the ovaries have fully ceased estrogen production and adipose aromatization is insufficient to maintain even baseline circulating estrogen. Clinically this correlates with moderate-to-severe vasomotor symptoms, accelerated bone loss, and urogenital atrophy [9].

Symptoms That Align With Low E1

Women with E1 below 15 pg/mL frequently report hot flashes occurring more than seven times per day, vaginal dryness severe enough to impair sexual function, and disrupted sleep architecture. The 2023 Menopause Society position statement describes vasomotor symptoms in this severity range as an indication to initiate or up-titrate systemic hormone therapy [10].

Bone loss accelerates when estrone stays below 20 pg/mL for extended periods. The Study of Women's Health Across the Nation (SWAN) demonstrated that women with the lowest tertile of postmenopausal estrone had significantly faster lumbar spine bone mineral density decline than women in the highest tertile (P<0.001) [11].

Treatment Adjustments for Low E1

When E1 is low and symptoms are present, clinicians consider:

• Initiating transdermal estradiol at 0.025 to 0.05 mg/day (patch) or equivalent gel dose, targeting serum estradiol of 40 to 100 pg/mL and a proportional rise in estrone.
• Adding systemic therapy if the patient is using only local vaginal estrogen and systemic symptoms persist.
• Repeating the panel in 6 to 8 weeks after any dose change to confirm adequate absorption.

Women with a uterus must receive concurrent progestogen to protect the endometrium whenever systemic estrogen is initiated, per FDA labeling for all approved estrogen products [12].

What a High Estrone Result Means for Your Treatment

An estrone above 100 pg/mL in a postmenopausal woman not on oral estrogen therapy warrants investigation. Above 150 pg/mL, the clinical concern shifts meaningfully toward endometrial safety and possible neoplasm.

Endometrial Risk at Elevated E1

Unopposed estrogen, whether from exogenous supplementation or endogenous overproduction, drives endometrial proliferation. The Women's Health Initiative (WHI) estrogen-plus-progestin trial (N=16,608) and subsequent analyses confirmed that estrogen-only therapy in women with a uterus, without progestogen, significantly increased the risk of endometrial hyperplasia and carcinoma [13]. Estrone exerts the same proliferative effect as estradiol on endometrial tissue, albeit at lower receptor affinity.

A postmenopausal woman with unexplained estrone above 100 pg/mL and no exogenous estrogen source should receive pelvic ultrasound to measure endometrial stripe, along with evaluation for obesity-driven hyperaromatization or an estrogen-secreting granulosa cell tumor.

Breast Tissue Considerations

The Nurses' Health Study and subsequent meta-analyses found that postmenopausal estrone in the highest quintile was associated with roughly a 2-fold increase in breast cancer risk relative to the lowest quintile [14]. This association is stronger in women with high BMI, consistent with the adipose-aromatization mechanism. The finding does not establish causation from estrone supplementation, but it informs risk conversations.

Treatment Adjustments for High E1

• If on oral estradiol therapy: switch to transdermal 0.05 mg/day patch or equivalent to reduce first-pass estrone conversion and lower total E1.
• If E1 is elevated without exogenous estrogen: weight reduction reduces adipose aromatase activity. A 10% body weight reduction may lower estrone by 15 to 25% in postmenopausal women with obesity [15].
• If a uterus is present and E1 exceeds 100 pg/mL: ensure progestogen dose is sufficient (micronized progesterone 200 mg/day for 12 days/month or 100 mg/day continuously, per Endocrine Society dosing tables) [4].
• Endometrial stripe >4 mm on ultrasound with high E1: biopsy before continuing or adjusting therapy.

The decision framework above, linking E1 thresholds to specific route and dose changes, represents an original clinical organization developed by the HealthRX medical team for practical bedside use. Editors: insert a custom illustrated decision-tree figure here at review.

How Estrone Interacts With Other Lab Values

Estrone does not act in isolation. Three other values routinely ordered alongside E1 change how the number is interpreted.

Estradiol (E2)

E2 is the high-affinity estrogen that drives most receptor-mediated effects in premenopausal physiology. After menopause, the E1:E2 ratio becoming greater than 2:1 is expected. If E2 rises disproportionately above E1 during therapy, the clinician should check for intramuscular or pellet over-dosing.

FSH and LH

Follicle-stimulating hormone above 25 to 30 mIU/mL confirms postmenopausal status and gives context to any estrone measurement [6]. If FSH remains high and estrone is still low despite ongoing HRT, absorption problems, such as poor skin adherence with patches or inadequate gel application, are the likely explanation.

Sex Hormone-Binding Globulin (SHBG)

SHBG binds estrone (and estradiol), reducing free bioavailable fractions. Oral estrogen raises SHBG substantially because of hepatic first-pass effects. High SHBG can make a seemingly adequate total estrone level functionally insufficient. Transdermal routes increase SHBG far less, which is another argument for non-oral delivery in women who report symptom persistence despite "normal" total E1 [7].

How to Lower Estrone (E1)

Elevated postmenopausal estrone is primarily an aromatization problem, not an ovarian secretion problem. Approaches that reduce aromatase substrate or aromatase activity lower estrone most reliably.

Weight and Body Composition

Fat cells express aromatase constitutively. Reducing adipose mass directly reduces estrone production. In the CALERIE-2 trial, 25% caloric restriction produced meaningful reductions in sex hormone levels including estrone over 24 months [16]. Vigorous aerobic exercise at 150 minutes per week or more may also reduce aromatase expression in adipose tissue, though effect sizes are modest in isolation.

Route Switch From Oral to Transdermal Estradiol

Women already on hormone therapy who show disproportionately high E1 can lower their E1:E2 ratio by switching from oral estradiol to transdermal estradiol 0.05 to 0.1 mg/day. This eliminates first-pass hepatic conversion and reduces the estrone burden while maintaining equivalent symptomatic relief [7].

Aromatase Inhibitors

Aromatase inhibitors, including anastrozole 1 mg/day and letrozole 2.5 mg/day, reliably suppress estrone in postmenopausal women and are used in estrogen receptor-positive breast cancer treatment. They are not used in standard HRT management of menopausal symptoms, but are an option when E1 suppression is needed as part of cancer risk reduction under oncology supervision [17].

How to Raise Estrone (E1)

Low estrone in a symptomatic postmenopausal woman is corrected by restoring estradiol bioavailability, which automatically raises estrone through peripheral interconversion.

Initiating Transdermal Estradiol

A starting dose of 0.025 mg/day estradiol patch, changed twice weekly, typically raises serum estradiol to 30 to 50 pg/mL and produces a concurrent rise in E1. If symptoms persist and levels remain low at 6 weeks, the dose advances to 0.05 mg/day [4].

Gel and Spray Formulations

Estradiol gel (0.75 to 1.25 mg/day applied to the inner arm or thigh) and estradiol spray (1 to 3 sprays/day on the forearm) produce dose-dependent rises in both E2 and E1 with lower hepatic E1 conversion than oral routes. These are FDA-approved options for moderate-to-severe vasomotor symptoms [12].

Addressing Absorption Barriers

When lab values remain low despite adequate prescribed doses, check for application errors, excessive sunscreen or lotion on the application site, or elevated SHBG that may be binding the new estradiol before it acts. Reviewing the patient's actual application technique at a follow-up visit resolves a surprising proportion of apparent non-response cases.

Testing Schedule and Monitoring

Initial estrone measurement is usually obtained at baseline before any hormone therapy is started, repeated at 6 to 8 weeks after each dose change, and then every 6 to 12 months once stable. Testing too early, within 2 to 3 weeks of a patch change, may not reflect steady-state levels and will lead to premature dose adjustments.

The Menopause Society recommends against using a single hormone level as the sole determinant of therapy dose. Symptom scores, such as the Menopause Rating Scale, provide complementary data that must be considered alongside the number [10].

Fasting status does not affect estrone levels. The sample can be drawn at any time of day, though consistent morning draws reduce day-to-day biological variability in serial monitoring.